Publications by authors named "Robert Haddad"

100Publications

Keynote 48: Is it really for everyone?

Oral Oncol 2020 06 4;105:104762. Epub 2020 May 4.

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104762DOI Listing
June 2020

Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma.

Oral Oncol 2020 07 11;106:104690. Epub 2020 Apr 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104690DOI Listing
July 2020

Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.

Oral Oncol 2020 06 3;105:104676. Epub 2020 Apr 3.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104676DOI Listing
June 2020

Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.

Oral Dis 2020 Mar 9;26(2):325-333. Epub 2020 Jan 9.

Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/odi.13218DOI Listing
March 2020

Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma.

Front Oncol 2019 27;9:815. Epub 2019 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718707PMC
August 2019

Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States.

Cancer Epidemiol Biomarkers Prev 2019 10 29;28(10):1660-1667. Epub 2019 Jul 29.

Department of Radiation Oncology, Head and Neck Oncology Program, Dana-Farber Cancer Institute, Brigham and Women's Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-19-0038DOI Listing
October 2019

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.

Oral Oncol 2019 08 20;95:120-126. Epub 2019 Jun 20.

Robert and Renée Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2019.06.019DOI Listing
August 2019

Active Learning of the Floor of Mouth Anatomy with Ultrasound.

Anat Sci Educ 2019 May 9;12(3):310-316. Epub 2018 Nov 9.

University of South Carolina School of Medicine, Columbia, South Carolina.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ase.1839
Publisher Site
http://dx.doi.org/10.1002/ase.1839DOI Listing
May 2019

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Oral Oncol 2018 10 17;85:29-34. Epub 2018 Aug 17.

Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 703-389-1895, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13688375183029
Publisher Site
http://dx.doi.org/10.1016/j.oraloncology.2018.08.005DOI Listing
October 2018

A Primary Care Ultrasound Fellowship: Training for Clinical Practice and Future Educators.

J Ultrasound Med 2019 Apr 4;38(4):1061-1068. Epub 2018 Sep 4.

Department of Internal Medicine, Palmetto Health-USC Medical Group, Palmetto Health-USC Medical Group, Columbia, South Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jum.14772DOI Listing
April 2019

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Cancer Treat Rev 2018 May 22;66:64-73. Epub 2018 Apr 22.

Dana-Farber Cancer Institute, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.007DOI Listing
May 2018

Management of elderly patients with locoregionally confined head and neck cancer.

Lancet Oncol 2017 05 26;18(5):e274-e283. Epub 2017 Apr 26.

Disease Center Leader, Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30229-2DOI Listing
May 2017

Advances in Collaborative Practice for Patients With Head and Neck Cancers.

J Adv Pract Oncol 2017 Apr 1;8(3):261-265. Epub 2017 Apr 1.

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003755PMC
April 2017

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

J Clin Oncol 2017 May 22;35(14):1542-1549. Epub 2017 Mar 22.

Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.1524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946724PMC
May 2017

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Endocrine 2017 Apr 3;56(1):121-128. Epub 2017 Feb 3.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-017-1233-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368192PMC
April 2017

Highlights in Head and Neck Cancer.

JAMA Oncol 2017 04;3(4):441-442

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3648DOI Listing
April 2017

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

N Engl J Med 2016 11 8;375(19):1856-1867. Epub 2016 Oct 8.

From the University of Pittsburgh Medical Center and Cancer Institute, Pittsburgh (R.L.F.); the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.B.); Centre Leon Berard, Lyon (J.F.), Centre Antoine Lacassagne, Nice (J.G.), and Institut Gustave Roussy, Villejuif (C.E.) - all in France; Stanford Cancer Institute, Stanford, CA (A.D.C.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan (L.L.); Institute of Cancer Research-Royal Marsden National Institute for Health Research Biomedical Research Centre, London (K.H.); University Hospital Essen, Essen, Germany (S.K.); University of Chicago, Chicago (E.E.V.); University of Michigan, Ann Arbor (F.W.); Winship Cancer Institute of Emory University, Atlanta (N.F.S.); Hospital Universitario 12 de Octubre, Madrid (L.C.I.D.); Dana-Farber Cancer Institute, Boston (R.H.); Universitätsspital Zurich, Zurich, Switzerland (T.R.); Kobe University Hospital, Kobe (N.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) - both in Japan; Bristol-Myers Squibb, Princeton, NJ (M.M., M.L., W.J.G., J.K., J.W.S.); and Ohio State University, Columbus (M.L.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564292PMC
November 2016

Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo.

Cancer 2016 12 20;122(23):3592-3595. Epub 2016 Sep 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30352DOI Listing
December 2016

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

J Clin Oncol 2016 11 30;34(32):3838-3845. Epub 2016 Sep 30.

Laura Q.M. Chow, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Robert Haddad, Dana-Farber Cancer Institute, Boston, MA; Shilpa Gupta and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Ranee Mehra, Fox Chase Cancer Center, Philadelphia, PA; Joseph Paul Eder and Barbara Burtness, Yale University Cancer Center, New Haven, CT; Hyunseok Kang, Johns Hopkins University, Baltimore, MD; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Amy Meister, Marisa Dolled-Filhart, Kumudu Pathiraja, and Jonathan D. Cheng, Merck, Kenilworth, NJ; Tanguy Y. Seiwert, The University of Chicago, Chicago, IL; Makoto Tahara, National Cancer Center Hospital East, Kashiwa; Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan; Raanan Berger, Sheba Medical Center, Tel Hashomer; Ravit Geva, Sourasky Medical Center, Tel-Aviv, Israel; Se-Hoon Lee and Bhumsuk Keam, Seoul National University Hospital; Hyun Cheol Chung, Yonsei University College of Medicine, Seoul, Korea; and Chia-Chi Lin, National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804896PMC
November 2016

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.

J Immunother Cancer 2016 21;4:32. Epub 2016 Jun 21.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Center, 450 Brookline Ave, DA L2-57, Boston, MA 02114 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0138-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915184PMC
June 2016

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Cancer Immunol Res 2016 08 16;4(8):679-87. Epub 2016 Jun 16.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0031DOI Listing
August 2016

Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer.

Head Neck 2016 10 15;38(10):1530-8. Epub 2016 Apr 15.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.24470DOI Listing
October 2016

Sequential and Concurrent Chemoradiation: State of the Art.

Hematol Oncol Clin North Am 2015 Dec 21;29(6):1061-74. Epub 2015 Oct 21.

Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2015.07.005DOI Listing
December 2015

Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers.

J Oncol Pract 2016 Jan 1;12(1):e77-82. Epub 2015 Sep 1.

Dana-Farber Cancer Institute; and Brigham and Women's Hospital, Boston, MA

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.2015.005124
Publisher Site
http://dx.doi.org/10.1200/JOP.2015.005124DOI Listing
January 2016

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium.

Eur J Cancer Prev 2016 07;25(4):344-8

aThe Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai bDepartment of Population Health, Division of Epidemiology, New York University School of Medicine cNew York Eye and Ear Infirmary, New York, New York dDepartment of Family and Preventive Medicine, Division of Public Health, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah ePenn State College of Medicine, Hershey, Pennsylvania fUniversity of North Carolina School of Public Health, Chapel Hill, North Carolina gNational Cancer Institute, Bethesda hJohns Hopkins Medical Institute iJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland jUniversity of California at Los Angeles School of Public Health, Los Angeles, California kDepartment of Epidemiology and Environmental Health Sciences, School of Public Health and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan lFred Hutchinson Cancer Research Center, Seattle, Washington mDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA nCatalan Institute of Oncology (ICO)-IDIBELL, L'Hospitalet de Llobregat oConsortium of Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain pUniversity of Sao Paulo, Sao Paulo qNational School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro rFederal University of Pelotas, Pelotas sHospital de Clinicas de Porto Alegre, Porto Alegre, Brazil tInternational Prevention Research Institute, Lyon, France uInstitute of Oncology Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina vInstitute of Oncology and Radiobiology, Havana, Cuba wMedical Informatics Center, Peking University, Beijing, China xDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752930PMC
July 2016

Head and Neck Cancers, Version 1.2015.

J Natl Compr Canc Netw 2015 Jul;13(7):847-55; quiz 856

From Memorial Sloan Kettering Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Duke Cancer Institute; Yale Cancer Center/Smilow Cancer Hospital; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; Vanderbilt-Ingram Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Mayo Clinic Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Fox Chase Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976490PMC
http://dx.doi.org/10.6004/jnccn.2015.0102DOI Listing
July 2015

New frontiers and treatment paradigms for thyroid carcinoma.

Clin Adv Hematol Oncol 2014 Jul;12(7 Suppl 14):3-21; quiz 22

The University of Texas, MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
July 2014

Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations.

J Oncol Pract 2015 Mar 27;11(2):151-4. Epub 2015 Jan 27.

Brigham and Women's Hospital; Dana-Farber Cancer Institute; Center for Clinical Excellence, Brigham and Women's Hospital, Boston, MA; and Center for Oncology Care at Erie County Medical Center, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2014.000414DOI Listing
March 2015

Barriers to clinical trial recruitment in head and neck cancer.

Oral Oncol 2015 Mar 13;51(3):203-11. Epub 2015 Jan 13.

Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2014.12.007DOI Listing
March 2015

Genomic analysis of metastatic cutaneous squamous cell carcinoma.

Clin Cancer Res 2015 Mar 14;21(6):1447-56. Epub 2015 Jan 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359951PMC
March 2015

Marital status and head and neck cancer outcomes.

Cancer 2015 Apr 18;121(8):1273-8. Epub 2014 Dec 18.

Harvard School of Dental Medicine, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29171DOI Listing
April 2015

Thyroid carcinoma, version 2.2014.

J Natl Compr Canc Netw 2014 Dec;12(12):1671-80; quiz 1680

From Memorial Sloan Kettering Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; University of Michigan Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Huntsman Cancer Institute at the University of Utah; Stanford Cancer Institute; City of Hope Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Roswell Park Cancer Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute; Duke Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0169DOI Listing
December 2014

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

N Engl J Med 2014 Oct;371(15):1426-33

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (N.W., E.M.V.A., N.G., R.I.H., D.J.K., P.A.J., L.A.G., J.H.L.), the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (N.W., E.M.V.A., Y.G., R.I.H., D.J.K., P.A.J., L.A.G., J.H.L.), the Departments of Pathology (J.A.B.) and Surgery (S.J.S., D.T.R.), Brigham and Women's Hospital, the Department of Medicine, Beth Israel Deaconess Medical Center (G.J.H.), and Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute (P.A.J.) - all in Boston; and Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard (N.W., E.M.V.A., A.A.-M., A.T.-W., M.R., G.G., D.J.K., S.L.C., D.M.S., L.A.G.), Whitehead Institute for Biomedical Research and the MIT Department of Biology (B.C.G., D.M.S.), and Howard Hughes Medical Institute, MIT (B.C.G., D.M.S.) - all in Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1403352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564868PMC
October 2014

Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.

Curr Treat Options Oncol 2014 Dec;15(4):595-610

Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-014-0309-1
Publisher Site
http://dx.doi.org/10.1007/s11864-014-0309-1DOI Listing
December 2014

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.

BMC Cancer 2014 Jun 28;14:473. Epub 2014 Jun 28.

Cancer Center, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914PMC
June 2014

Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

J Clin Oncol 2014 Aug 28;32(23):2408-15. Epub 2014 Apr 28.

Gypsyamber D'Souza, Shirani Rajan, and Jennifer Gerber, Johns Hopkins Bloomberg School of Public Health; Sara I. Pai, Johns Hopkins Medical Institutions, Baltimore, MD; Neil D. Gross, Oregon Health and Science University, Portland, OR; Robert Haddad, Dana-Farber Cancer Institute, Boston, MA; Karen S. Anderson, Arizona State University, Tempe, AZ; Maura L. Gillison, Ohio State University Comprehensive Cancer Center, Columbus, OH; and Marshall R. Posner, Icahn School of Medicine at Mount Sinai, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.1341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263818PMC
August 2014

Human papillomavirus-associated adenocarcinoma of the palatine tonsil--reply.

Hum Pathol 2014 Apr 19;45(4):895. Epub 2013 Dec 19.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2013.09.022DOI Listing
April 2014

Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.

Cancer Treat Rev 2014 Apr 14;40(3):390-404. Epub 2013 Sep 14.

Cancer Center, Department of Medical Oncology and Head and Neck Surgery, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372130019
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2013.09.007DOI Listing
April 2014

How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer.

Authors:
Robert I Haddad

J Clin Oncol 2013 Oct 3;31(29):3618-20. Epub 2013 Sep 3.

Dana-Farber Cancer Institute, Harvard Medical School; and Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.5098DOI Listing
October 2013

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

J Natl Compr Canc Netw 2013 Aug;11(8):917-23

From 1Memorial Sloan-Kettering Cancer Center; 2The University of Texas MD Anderson Cancer Center; 3Duke Cancer Institute; 4Fox Chase Cancer Center; 5Massachusetts General Hospital Cancer Center; 6Moffitt Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8Stanford Cancer Institute; 9The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 10The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 11Dana-Farber/Brigham and Women's Cancer Center; 12Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 13Roswell Park Cancer Institute; 14Huntsman Cancer Institute at the University of Utah; 15UNMC Eppley Cancer Center at The Nebraska Medical Center; 16City of Hope Comprehensive Cancer Center; 17University of Washington/Seattle Cancer Care Alliance; 18Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20University of Alabama at Birmingham Comprehensive Cancer Center; 21University of Michigan Comprehensive Cancer Center; 22UCSF Helen Diller Family Comprehensive Cancer Center; and 23National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0113DOI Listing
August 2013